Bio-Techne (TECH) Expected to Announce Earnings on Wednesday

Key Points

• Bio-Techne will report Q3 2026 results before the market opens on Wednesday, May 6, 2026 at 9:00 AM ET, with analysts forecasting $0.55 EPS and $316.12M in revenue.
• In the prior quarter the company beat expectations, posting $0.46 EPS versus $0.43 expected and $295.88M in revenue, and analysts now project about $2.00 EPS for the current and next fiscal year.
• The stock trades with a market cap of $8.37B and a high PE (~104.9); Wall Street’s consensus is a Moderate Buy with a $72.77 average price target, and the shares carry a 0.6% dividend yield.

Bio-Techne (NASDAQ:TECH - Get Free Report) is expected to be releasing its Q3 2026 results before the market opens on Wednesday, May 6th. Analysts expect Bio-Techne to post earnings of $0.55 per share and revenue of $316.1210 million for the quarter. Interested persons may visit the the company's upcoming Q3 2026 earning results page for the latest details on the call scheduled for Wednesday, May 6, 2026 at 9:00 AM ET.

Bio-Techne (NASDAQ:TECH - Get Free Report) last issued its quarterly earnings results on Wednesday, February 4th. The biotechnology company reported $0.46 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.43 by $0.03. The firm had revenue of $295.88 million for the quarter, compared to analysts' expectations of $290.20 million. Bio-Techne had a return on equity of 13.94% and a net margin of 6.67%.The firm's revenue for the quarter was down .4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.42 EPS. On average, analysts expect Bio-Techne to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Bio-Techne Stock Performance

Shares of TECH stock opened at $53.51 on Wednesday. The stock has a market capitalization of $8.37 billion, a PE ratio of 104.92, a price-to-earnings-growth ratio of 3.62 and a beta of 1.49. Bio-Techne has a 52-week low of $46.05 and a 52-week high of $72.16. The stock's 50-day moving average price is $54.92 and its 200 day moving average price is $59.82. The company has a quick ratio of 3.08, a current ratio of 4.54 and a debt-to-equity ratio of 0.13.

Bio-Techne Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, February 27th. Investors of record on Monday, February 16th were given a $0.08 dividend. This represents a $0.32 annualized dividend and a yield of 0.6%. The ex-dividend date was Friday, February 13th. Bio-Techne's payout ratio is 62.75%.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on TECH. UBS Group restated a "buy" rating and issued a $79.00 price target (up from $70.00) on shares of Bio-Techne in a research report on Thursday, February 5th. Citigroup restated a "buy" rating and issued a $80.00 price target (up from $70.00) on shares of Bio-Techne in a research report on Wednesday, February 4th. Robert W. Baird set a $70.00 price target on Bio-Techne in a research report on Thursday, February 5th. Weiss Ratings cut Bio-Techne from a "hold (c-)" rating to a "sell (d+)" rating in a research report on Friday, March 27th. Finally, Evercore boosted their price target on Bio-Techne from $62.00 to $68.00 and gave the company an "in-line" rating in a research report on Thursday, February 5th. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $72.77.

Institutional Investors Weigh In On Bio-Techne

Several institutional investors have recently modified their holdings of TECH. Wellington Management Group LLP boosted its stake in shares of Bio-Techne by 349.8% during the 3rd quarter. Wellington Management Group LLP now owns 5,115,133 shares of the biotechnology company's stock worth $284,555,000 after acquiring an additional 3,978,026 shares in the last quarter. Durable Capital Partners LP purchased a new stake in shares of Bio-Techne during the 3rd quarter worth approximately $77,658,000. Morgan Stanley boosted its stake in shares of Bio-Techne by 15.3% during the 4th quarter. Morgan Stanley now owns 8,345,414 shares of the biotechnology company's stock worth $490,794,000 after acquiring an additional 1,107,536 shares in the last quarter. Schroder Investment Management Group purchased a new stake in shares of Bio-Techne during the 4th quarter worth approximately $51,067,000. Finally, Maverick Capital Ltd. boosted its stake in shares of Bio-Techne by 27.8% during the 4th quarter. Maverick Capital Ltd. now owns 3,850,923 shares of the biotechnology company's stock worth $226,473,000 after acquiring an additional 838,269 shares in the last quarter. Hedge funds and other institutional investors own 98.95% of the company's stock.

Bio-Techne Company Profile

Bio-Techne Corporation NASDAQ: TECH is a global life sciences company that develops, manufactures and sells high-quality reagents, instruments and services for the research, diagnostic and bioprocessing markets. Its core product offerings include recombinant proteins, antibodies, immunoassays, nucleic acid probes and kits, single-cell analysis solutions and automated protein analysis systems. Flagship brands such as R&D Systems, Novus Biologicals, ProteinSimple and Advanced Cell Diagnostics provide researchers and clinicians with reliable tools for cell biology, immunology, proteomics and genomics applications.

Headquartered in Minneapolis, Minnesota, Bio-Techne serves customers across North America, Europe and the Asia-Pacific region through a combination of direct sales, distributors and strategic partnerships.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.